In ultra-fast FDA nod, Bristol Myers’ Opdivo catapults I-O to presurgery lung cancer with a first glimpse of key data

When lots of regulatory priorities are given to COVID-19 products during the pandemic, the FDA has doled out an ultra-fast cancer approval within the same week of accepting an application, introduc | When lots of regulatory priorities are given to COVID-19 during the pandemic, the FDA has introduced Opdivo as the first presurgery therapy for early-stage non-small cell lung cancer, with an ultra-fast approval within the same week of accepting its application.